Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 1, 2000, Pages 78-87

  Barnett, J M ^a   Cadman, A ^a   Gor, D ^a   Dempsey, M ^a   Walters, M ^a   Candlin, A ^a   Tisdale, M ^a   Morley, P J ^a   Owens, I J ^a   Fenton, R J ^a   Lewis, A P ^a   Claas, E C J ^b   Rimmelzwaan, G F ^b   De Groot, R ^c   Osterhaus, A D M E ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; SIALIDASE; ZANAMIVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG SENSITIVITY; FEMALE; INFLUENZA; INFLUENZA VIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS SHEDDING;

EID: 17344383981     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.1.78-87.2000     Document Type: Article

References (31)

1. Blick, T. J., A. Sahasrabudhe, M. McDonald, I. J. Owens, P. J. Morley, R. J. Fenton, and J. L. McKimm-Breschkin. 1998. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. Virology 246:95-103.
2. Blick, T. J., T. Tiong, A. Sahasrabudhe, J. N. Varghese, P. M. Colman, G. J. Hart, R. C. Bethell, and J. L. McKimm-Breschkin. 1995. Generation and characterization of an influenza virus neuraminidase variant with decreased susceptibility to the neuraminidase-specific inhihitor 4-guanidino-Neu5Ac2en. Virology 214:475-484.
3. Campion, K., C. Silagy, C. Cooper, P. Bolton, R. Watts, T. Liaw, K. Narayan, F. Delooze, and the MIST Study Group. 1998. Efficacy and safety of inhaled zanamivir in the treatment of influenza A and B virus infections. Lancet 352:1877-1881.
4. Colacino, J. M., N. Y. Chirgadze, E. Garman, K. G. Murti, R. J. Loncharich, A. J. Baxter, K. A. Staschke, and W. G. Laver. 1997. A single sequence change destabilizes the influenza virus neuraminidase tetramer. Virology 236:66-75.
5. Doherty, R. M. 1964. Animal virus titration techniques, p. 169-223. In R. J. C. Harris (ed.), Techniques in experimental virology. Academic Press, New York, N. Y.
6. Goto, H., R. C. Bethell, and Y. Kawaoka. 1997. Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-Neu5Ac2en. Virology 238:265-272.
7. Gubareva, L. V., M. N. Matrosovitch, M. D. Brenner, R. C. Bethell, and R. G. Webster. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1257-1262.
8. Gubareva, L. V., M. J. Robinson, R. C. Bethell, and R. G. Webster. 1997. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J. Virol. 71: 3385-3390.
9. Gubareva, L. V., R. Bethell, G. J. Hart, K. G. Murti, C. R. Penn, and R. G. Webster. 1996. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J. Virol. 70:1818-1827.
10. Gubareva, L. V., C. R. Penn, and R. G. Webster. 1995. Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 212:323-330.
11. Hayden, F. G., A. D. M. E. Osterhaus, J. J. Treanor, D. M. Fleming, F. Y. Aoki, K. G. Nicholson, A. M. Bohnen, H. M. Hirst, O. Keene, and K. Wightman. 1997. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N. Engl. J. Med. 337:874-880.
12. Hayden, F. G. 1996. Amantadine and rimantadine - clinical aspects, p. 59-77. In D. D. Richman (ed.), Antiviral drug resistance. John Wiley & Sons Ltd., New York, N. Y.
13. Hayden, F. G., J. J. Treanor, R. F. Belts, M. Lobo, J. D. Esinhart, and E. K. Hussey. 1996. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 275:295-299.
14. Hayden, F. G., R. B. Belshe, R. D. Clover, A. J. Hay, M. G. Oakes, and W. Soo. 1989. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N. Engl. J. Med. 321:1695-1702.
15. Houck, P., M. Hemphill, S. LaCroix, D. Hirsh, and N. Cox. 1995. Amantadine-resistant influenza A in nursing homes. Identification of a resistant virus prior to drug use. Arch. Intern. Med. 155:533-537.
16. McKimm-Breschkin, J. L., A. Sahasrabudhe, T. J. Blick, M. McDonald, P. M. Colman, G. J. Hart, R. C. Bethell, and J. N. Varghese. 1998. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J. Virol. 72:2456-2462.
17. McKimm-Breschkin, J. L., T. J. Blick, A. Sahasrabudhe, T. Tiong, D. Marshall, G. J. Hart, R. C. Bethell, and C. R. Penn. 1996. Generation and characterization of variants of NWS/G7OC influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob. Agents Chemother. 40:40-46.
18. McKimm-Breschkin, J. L. M. McDonald, T. J. Blick, and P. M. Colman. 1996. Mutation in the influenza virus neuraminidase gene resulting in decreased susceptibility to the neuramindiase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme. Virology 225:240-242.
19. Monto, A. S., D. P. Robinson, L. Herlocher, J. M. Hinson, M. Elliott, and O. Keene. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J. Infect. Dis., in press.
20. Nicholson, K. G. 1996. Use of antivirals in influenza in the elderly: prophylaxis and therapy. Gerontology 42:280-289.
21. Penn, C. R., J. M. Barnett, R. C. Bethell, R. Fenton, K. L. Gearing, N. Healy, and A. J. Jowett. 1996. Selection of influenza virus with reduced susceptibility in vitro to the neuraminidase inhibitor GG167 (4-guanidino-Neu5Ac2en): changes in the haemagglutinin may compensate for loss of neuraminidase activity, p. 735-740. In L. E. Brown, A. W. Hampson, and R. G. Webster (ed.), Options for the control of influenza III. Elsevier Science B. V., Amsterdam, The Netherlands.
22. Potier, M., L. Mameli, M. Belisle, L. Dallaire, and S. B. Melancon. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-D-N-acetylneuraminate) substrate. Anal. Biochem. 94:287-296.
23. Rocha, E., X. Xu, H. E. Hall, J. R. Allen, H. L. Regnery, and N. J. Cox. 1993. Comparison of 10 influenza A (H1N1 and H3N2) haemagglutinin sequences obtained directly from clinical specimens to those of cell- and egg-grown viruses. J. Gen. Virol. 74:2513-2518.
24. Ryan, D. M., J. Ticehurst, and M. H. Dempsey. 1995. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob. Agents Chemother. 39:2583-2584.
25. Ryan, D., J. Ticehurst, M. H. Dempsey, and C. R. Penn. 1994. Inhibition of influenza virus replication in mice by GG167 is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob. Agents Chemother. 38:2270-2275.
26. Sahasrabudhe, A., L. Lawrence, V. C. Epa, J. N. Varghese, P. M. Colman, and J. L. McKimm-Breschkin. 1998. Substrate, inhibitor, or antibody stabilizes the Glu 119 Gly mutant influenza virus neuraminidase. Virology 247: 14-21.
27. Staschke, K. A., J. M. Colacino, A. J. Baxter, G. M. Air, A. Bansal, W. J. Hornback, J. E. Munroe, and G. W. Laver. 1995. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 214: 642-646.
28. Thomas, G. P., M. Forsyth, C. R. Penn, and J. W. McCauley. 1994. Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-2,3-N-acetylneuraminic acid. Antivir. Res. 24:352-356.
29. von Itzstein, M., W. Y. Wu, G. B. Kok, M. S. Pegg, J. C. Dyason, B. Jin, T. Van Phan, M. L. Smythe, H. F. White, S. W. Oliver, P. M. Colman, J. N. Varghese, D. M. Ryan, J. M. Woods, R C. Bethell, V. J. Hotham, J. M. Cameron, and C. R. Penn. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 343:418-423.
30. Webster, R. G., K. F. Shortridge, and Y. Kawaoka. 1997. Influenza: interspecies transmission and emergence of new pandemics. FEMS Immunol. Med. Microbiol. 18:275-279.
31. Woods, J. M., R. C. Bethell, J. A. V. Coates, N. Healy, S. A. Hiscox, B. A. Pearson, D. M. Ryan, J. Ticehurst, J. Tilling, S. M. Walcott, and C. R. Penn. 1993. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. 37:1473-1479.